Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)
Status:
Terminated
Trial end date:
2018-07-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the investigational treatment volixibat (SHP626)
is safe, tolerable and effective in adults with nonalcoholic steatohepatitis (NASH).